Back to results
US 11,891,380 B2Granted
Solid state forms of Belumosudil and Belumosudil salts
AssigneeTeva Pharmaceuticals International GmbH
InventorsPolina Lapido, Inbal Shumacher, Ofir Shaul
Life of this patent
Estimating the term…
Abstract
The present disclosure encompasses solid state forms of Belumosudil, in embodiments crystalline polymorphs of Belumosudil or salts thereof, processes for preparation thereof, and pharmaceutical compositions thereof.
Claims16
A crystalline form of Belumosudil Mesylate designated form M2, which is characterized by data selected from one or more of the following:
- (a) an XRPD pattern having peaks at 6.3, 12.8, 15.8, 19.3 and 26.5 degrees 2-theta±0.2 degrees 2-theta;
- (b) an XRPD pattern substantially as depicted in FIG. 7;
- (c) an XRPD pattern having peaks at 6.3, 12.8, 15.8, 19.3 and 26.5 degrees 2-theta±0.2 degrees 2-theta, and also having any one, two, three, four or five additional peaks selected from 7.8, 20.4, 23.7, 25.1 and 27.4 degrees two theta±0.2 degrees two theta;
- (d) an X-ray powder diffraction pattern having peaks at 6.3, 7.8, 12.8, 15.8, 19.3, 20.4, 23.7, 25.1, 26.5 and 27.4 degrees 2-theta±0.2 degrees 2-theta;
- (e) a solid state 13C NMR spectrum with characteristic peaks at 156.1, 132.7, 135.5, 119.8 and 110.9 ppm±0.2 ppm;
- (f) a solid state 13C NMR spectrum having the following chemical shift absolute differences from reference peak at 166.9 ppm±1 ppm:
- 10.8, 34.2, 36.4, 47.1 and 56.0 ppm±0.1 ppm;
- (g) a solid state 13C NMR spectrum substantially as depicted in FIG. 19, 20 or 21;
- and
- (h) combinations of these data.
7 more elements
Dependencies are inferred from the claim text.